Bayer was founded in the year 1863 in Barmen in North Rhine Westphalia in the west of what was then the Kingdom of Prussia, today modern Germany. "What started as a small but innovative dyestuffs ...

In a bold move to restore $540 million in cost savings, Bayer ... of Nubeqa - a drug that’s already generated over $1 billion USD. The company offers a complex portfolio, from aspirin and ...

King in those last days of his life was speaking to how the environment and the conditions in which people live and work ...

Bayer is pressing ahead with a phase ... with prior ischaemic stroke or high-risk TIA, on top of aspirin and antiplatelet therapy. The drug numerically reduced the risk of clinical ischaemic ...

.Semaglutide: Novo Nordisk Semaglutide is a long-acting oral GLP-1 analogue being developed and investigated by Novo Nordisk. The drug is currently being evaluated under Phase III clinical trial for ...

Germany is widely recognized as one of the leading countries in the pharmaceutical industry boasting a rich history of innovation cutting-edge research and global influence With its well-established i ...

Benefiting from technological and conceptual groundwork and positive early data, gene therapies are advancing in the clinic ...

Whether ahead of their time, truly bizarre, or just plain doomed, it’s certainly interesting to see companies go completely off-script. (The Zappos experiment with “Holocracy” memorably comes to mind.

Partially offsetting this are declines in cardiovascular drug Xarelto ... margins. Bayer’s healthcare segment also includes a consumer healthcare business with leading brands Aspirin and Aleve.

An experimental menopause drug from Bayer succeeded in a late-stage trial in women taking drugs to treat or prevent breast cancer, the company said Thursday. Bayer said the drug, elinzanetant ...